Abstract
Infectious disease outbreaks with pandemic potential present challenges for mitigation and control. Policymakers make decisions to reduce disease-associated morbidity and mortality while also minimizing socioeconomic costs of control. Despite ongoing efforts and widespread recognition of the challenge, there remains a paucity of decision tool frameworks that integrate epidemic and macroeconomic dynamics. Here, we propose and analyze an econo-epidemic model to identify robust planning policies to limit epidemic impacts while maintaining economic activity. The model couples epidemic dynamics, behavioral change, economic activity, and feasible policy plans informed by respiratory disease threats of pandemic concern. We compare alternative fixed, dynamic open-loop optimal control, and feedback control policies via a welfare loss framework. We find that open loop policies that adjust employment dynamically while maintaining a flat epidemic curve in advance of the uncertain arrival of population-scale vaccination outperform fixed employment reduction policies. However, open loop policies are highly sensitive to misestimation of parameters associated with intrinsic disease strength and feedback between economic activity and transmission, leading to potentially significant increases in welfare loss. In contrast, feedback control policies guided by open loop dynamical targets of the time-varying reproduction number perform near-optimally when parameters are well-estimated, while significantly outperforming open loop policies whenever disease features and population-scale behavioral response are misestimated – as they inevitably are. These findings present a template for integrating principled economic models with epidemic scenarios to identify vulnerabilities in policy responses and expand policy options in preparation for future pandemics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Simons Foundation grant 930382 (to JSW) and support from the Chaires Blaise Pascal program of the Île-de-France region (to JSW).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.